Literature DB >> 16831073

Laparoscopic and robotic radical prostatectomy.

Carter Q Le1, Matthew T Gettman.   

Abstract

Radical retropubic prostatectomy is the current gold standard for surgical removal of the prostate gland. Recently, laparoscopic radical prostatectomy has been developed in an attempt to decrease surgical morbidity, and the technical difficulty of laparoscopy has been countered with the development of the da Vinci robotic interface. Studies that have compared the minimally invasive approaches with the traditional open approach have reported comparable perioperative outcomes. While long-term oncological data are available for open prostatectomy, there are only short-term studies available for laparoscopic prostatectomy. Functional outcomes, including urinary continence and sexual function, appear to be similar between the surgical approaches in the short term. However, currently, costs appear to favor open surgery, with the da Vinci-assisted prostatectomy having the highest expenses. Longer-term data are required to confidently determine the optimal balance between morbidity, oncological efficacy, functional outcomes and cost among the differing surgical approaches.

Mesh:

Year:  2006        PMID: 16831073     DOI: 10.1586/14737140.6.7.1003

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  2 in total

Review 1.  The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging.

Authors:  Steven D Allen; Alan Thompson; S Aslam Sohaib
Journal:  Eur Radiol       Date:  2008-02-13       Impact factor: 5.315

2.  Label-free high-resolution imaging of prostate glands and cavernous nerves using coherent anti-Stokes Raman scattering microscopy.

Authors:  Liang Gao; Haijun Zhou; Michael J Thrall; Fuhai Li; Yaliang Yang; Zhiyong Wang; Pengfei Luo; Kelvin K Wong; Ganesh S Palapattu; Stephen T C Wong
Journal:  Biomed Opt Express       Date:  2011-03-18       Impact factor: 3.732

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.